Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Paul Korner has been appointed chief medical officer of Agile Therapeutics. Most recently, Korner was senior vice president of clinical development and medical affairs at Axovant Gene Therapies.
Richard Walsh has been named CEO of Corvent Medical. Walsh was previously vice president of global sales for Medrobotics.
George Thaw has been appointed interim CEO of digital healthcare solutions provider FRISQ. Thaw was most recently CEO of Fuel3D.
Ikena Oncology has named Sergio Santillana chief medical officer. Formerly, Santillana was chief medical officer at Merrimack Pharmaceuticals.
InStep Health has named Lloyd Cochran executive vice president and chief financial officer. Cochran was previously chief operating officer of Bulltech Services. Dan Wilmer, InStep’s chief product officer, has expanded his responsibilities as the company’s new executive vice president.
Robert Stein has been appointed executive vice president of R&D at MiMedX. Stein previously served as senior adviser of R&D at Agenus.
Mind Medicine has appointed Miri Wernli as president of the company’s clinical development strategy. Wernli most recently served as CEO of Creso Pharma.
NBE-Therapeutics has found its newest CEO in Bertrand Damour, the former CEO of Synthena.
Pacific Biosciences has named Christian Henry its president and CEO. Henry was previously the chief commercial officer of Illumina.
Kerensa Jimenez has been named CEO of Paragon Biosciences. Jimenez was most recently a managing director at Octagon Capital Group.
Dennis Zaller, former executive director of integrative sciences at Celgene, has been named chief scientific officer at ROME Therapeutics.
James Hussey has taken the helm at Seneca Therapeutics as the company’s CEO. Hussey joins Seneca from his own consulting company, where he provided C-suite consulting services for biotech and pharma companies.
Slayback Pharma has named Lori Hoffman head of alliance management. Hoffman previously served as senior director of alliance management at Frontida BioPharm.
Swedish Orphan Biovitrum
Ravi Rao has been appointed head of R&D at Swedish Orphan Biovitrum. Rao’s most recent position was as chief medical officer at Aeglea Biotherapeutics.
Tarsus Pharmaceuticals has named Aziz Mottiwala the company’s chief commercial officer. Formerly, Mottiwala was chief commercial officer at Opiant Pharmaceuticals.
TYME Technologies has appointed John Rothman to the role of executive vice president of product development. Prior to this appointment, Rothman was director of clinical research at Roche.
Manasi Jaiman has been appointed vice president of clinical development at ViaCyte. Jaiman previously served as senior medical director at Covance Clinical Development Services.
Ellen Lubman has been hired as chief business officer of Werewolf Therapeutics. Lubman was most recently chief business officer at Impel NeuroPharma.